Mandik-Nayak L - Search Results

1

The Immunomodulatory Enzyme IDO2 Mediates Autoimmune Arthritis through a Nonenzymatic Mechanism.

Merlo LMF, Peng W, DuHadaway JB, Montgomery JD, Prendergast GC, Muller AJ, Mandik-Nayak L. Merlo LMF, et al. Among authors: mandik nayak l. J Immunol. 2022 Feb 1;208(3):571-581. doi: 10.4049/jimmunol.2100705. Epub 2021 Dec 29. J Immunol. 2022. PMID: 34965962 Free PMC article.

2

The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity.

Scott GN, DuHadaway J, Pigott E, Ridge N, Prendergast GC, Muller AJ, Mandik-Nayak L. Scott GN, et al. J Immunol. 2009 Jun 15;182(12):7509-17. doi: 10.4049/jimmunol.0804328. J Immunol. 2009. PMID: 19494274 Free PMC article.

3

IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation.

Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LM, Pigott E, Keough MP, Rust S, Mellor AL, Mandik-Nayak L, Muller AJ, Prendergast GC. Metz R, et al. Int Immunol. 2014 Jul;26(7):357-67. doi: 10.1093/intimm/dxt073. Epub 2014 Jan 8. Int Immunol. 2014. PMID: 24402311 Free PMC article.

4

IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis.

Merlo LMF, Pigott E, DuHadaway JB, Grabler S, Metz R, Prendergast GC, Mandik-Nayak L. Merlo LMF, et al. J Immunol. 2014 Mar 1;192(5):2082-2090. doi: 10.4049/jimmunol.1303012. Epub 2014 Jan 31. J Immunol. 2014. PMID: 24489090 Free PMC article.

5

IDO2 in Immunomodulation and Autoimmune Disease.

Prendergast GC, Metz R, Muller AJ, Merlo LM, Mandik-Nayak L. Prendergast GC, et al. Front Immunol. 2014 Nov 20;5:585. doi: 10.3389/fimmu.2014.00585. eCollection 2014. Front Immunol. 2014. PMID: 25477879 Free PMC article. Review.

6

IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism.

Merlo LM, DuHadaway JB, Grabler S, Prendergast GC, Muller AJ, Mandik-Nayak L. Merlo LM, et al. J Immunol. 2016 Jun 1;196(11):4487-97. doi: 10.4049/jimmunol.1600141. Epub 2016 Apr 25. J Immunol. 2016. PMID: 27183624 Free PMC article.

7

IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity.

Merlo LM, Mandik-Nayak L. Merlo LM, et al. Clin Med Insights Pathol. 2016 Nov 21;9(Suppl 1):21-28. doi: 10.4137/CPath.S39930. eCollection 2016. Clin Med Insights Pathol. 2016. PMID: 27891058 Free PMC article. Review.

8

Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.

Merlo LMF, Grabler S, DuHadaway JB, Pigott E, Manley K, Prendergast GC, Laury-Kleintop LD, Mandik-Nayak L. Merlo LMF, et al. Clin Immunol. 2017 Jun;179:8-16. doi: 10.1016/j.clim.2017.01.016. Epub 2017 Feb 20. Clin Immunol. 2017. PMID: 28223071 Free PMC article.

9

Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers.

Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis M, Villatoro T, Leiby BE, Mandik-Nayak L, Winter JM, Yeo CJ, Prendergast GC, Brody JR. Nevler A, et al. Among authors: mandik nayak l. Clin Cancer Res. 2019 Jan 15;25(2):724-734. doi: 10.1158/1078-0432.CCR-18-0814. Epub 2018 Sep 28. Clin Cancer Res. 2019. PMID: 30266763 Free PMC article.

10

IDO1 Signaling through GCN2 in a Subpopulation of Gr-1⁺ Cells Shifts the IFNγ/IL6 Balance to Promote Neovascularization.

Dey S, Mondal A, DuHadaway JB, Sutanto-Ward E, Laury-Kleintop LD, Thomas S, Prendergast GC, Mandik-Nayak L, Muller AJ. Dey S, et al. Among authors: mandik nayak l. Cancer Immunol Res. 2021 May;9(5):514-528. doi: 10.1158/2326-6066.CIR-20-0226. Epub 2021 Feb 23. Cancer Immunol Res. 2021. PMID: 33622713

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

43 results

Search Page